真实世界中FLT3-ITD阳性急性髓系白血病诱导疗效及预后因素分析
该真实世界研究纳入114例初发FLT3-ITD(+)AML患者,分析诱导治疗疗效及预后因素。伴预后良好基因患者1个疗程和2个疗程CR率均显著高于其他类型患者(P<0.05)。对1个疗程未缓解的其他类型患者,索拉非尼联合化疗较常规化疗显著提高CR率(P<0.05),但总生存和无病生存无显著差异。
要点
- 伴预后良好基因的FLT3-ITD(+)AML患者1个疗程CR率67.3%,2个疗程CR率83.3%。
- 其他类型FLT3-ITD(+)AML患者1个疗程CR率35.5%,2个疗程CR率64.8%。
- 其他类型1个疗程未缓解者,索拉非尼联合化疗CR率66.7% vs 常规化疗30.4%(P<0.05)。
核心结论
- FLT3-ITD(+)AML患者整体预后不良,通过索拉非尼联合化疗对不伴随预后良好基因突变的FLT3-ITD(+)AML进行分层治疗可以提高疗效。
研究设计与样本
- 真实世界研究,纳入2013年1月至2016年12月初发FLT3-ITD(+)AML患者114例,男75例、女39例,中位年龄42岁(范围14-72岁)。
- 所有患者至少完成1个疗程诱导化疗并随访,采用MICM评估疗效,卡方检验比较率,Kaplan-Meier法估计生存,Cox比例风险模型识别独立预后因素。
主要发现
- 114例中伴预后良好基因突变52例(NPM1突变46例,RUNX1-RUNX1T1 5例,CEBPA双突变1例),其他类型62例。
- 所有患者1个疗程CR率50.0%(57/114),2个疗程CR率72.5%(74/104)。
- 伴预后良好基因患者1个疗程CR率67.3%(35/52),2个疗程CR率83.3%(40/48);其他类型患者1个疗程CR率35.5%(22/62),2个疗程CR率64.8%(35/54);两组CR率差异有统计学意义(P<0.05)。
- 其他类型1个疗程未缓解患者中,索拉非尼联合化疗组9例中6例达CR(66.7%),常规化疗组23例中7例达CR(30.4%),差异有统计学意义(χ²=4.47,P<0.05)。
- 索拉非尼联合化疗与常规化疗组总生存和无病生存比较差异均无统计学意义(P值分别为0.641和0.517)。
关键数值与推荐
- 1个疗程CR率:伴预后良好基因患者67.3%(35/52) vs 其他类型患者35.5%(22/62)。
- 2个疗程CR率:伴预后良好基因患者83.3%(40/48) vs 其他类型患者64.8%(35/54)。
- 其他类型1个疗程未缓解患者CR率:索拉非尼联合化疗66.7%(6/9) vs 常规化疗30.4%(7/23),χ²=4.47,P<0.05。
- 总生存比较:索拉非尼联合化疗 vs 常规化疗,P=0.641;无病生存比较:P=0.517。
临床怎么用
- 对初发FLT3-ITD(+)AML患者应检测伴随基因突变,伴预后良好基因突变者诱导治疗疗效相对较好。
- 对不伴随预后良好基因突变且1个疗程未缓解的FLT3-ITD(+)AML患者,可考虑索拉非尼联合化疗以提高CR率。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and prognostic factors of induction therapy in FLT3-ITD(+) acute myeloid leukemia (AML) in the real world data. Methods: From January 2013 to December 2016, 114 de novo patients with FLT3-ITD(+)AML were enrolled in this study. Out of 114 cases, 75 were male, and 39 were female. The median age was 42 years old (ranged from 14 to 72 years old) . The chemotherapy regimens were used for induction therapy and all cases were followed up. The treatment response was evaluated by MICM and the comparison of the ratio were analyzed by chi-square test and the survival was estimated by Kaplan-Meier analysis and Cox proportional hazards model was used to identify independent prognostic factors. Results: There were 52 FLT3-ITD(+)AML patients with favorable prognosis genes (46 cases with NPM1, 5 cases with RUNX1-RUNX1T1, 1 case with CEBPA double mutation) and 62 patients with other types of FLT3-ITD(+)AML at diagnosis. All patients completed at least one cycle of induction therapy and the clinical curative effect was evaluated, complete remission (CR) rate was 50.0% (57/114) in one cycle and total CR rate was 72.5% (74/104) in two cycles. The CR rate of the FLT3-ITD(+) AML patients with favorable prognosis genes was 67.3% (35/52) in one cycle and 83.3% (40/48) in two cycles; for the other types FLT3-ITD(+)AML patients, the CR rate was 35.5% (22/62) in one cycle and 64.8% (35/54) in two cycles. There was a significant difference in CR rate between the FLT3-ITD(+)AML patients with and without favorable prognosis genes (P<0.05) . This indicates that the FLT3-ITD(+)AML patients with favorable prognosis gene had relatively good therapeutic effect. Among other types of FLT3-ITD(+)AML patients who did not achieve remission from one cycle of chemotherapy, 9 patients were given sorafenib plus chemotherapy and 6 cases (66.7%) achieved CR; 23 patients were given conventional chemotherapy and 7 cases (30.4%) achieved CR. There was a significant difference between sorafenib plus chemotherapy and conventional chemotherapy groups (χ(2)=4.47, P<0.05) and this indicates that sorafenib plus chemotherapy can significantly improve the CR rate of FLT3-ITD(+)AML patients. Comparing overall survival (OS) and disease free survival (DFS) , there was no significant difference between sorafenib plus chemotherapy and conventional chemotherapy groups (P values were 0.641 and 0.517, respectively) . Conclusion: The overall prognosis of FLT3-ITD(+)AML patients is poor, and the stratification therapeutic efficacy of FLT3-ITD(+)AML without favorable prognosis gene can be improved by sorafenib combined with chemotherapy. 目的: 探讨真实世界FLT3-ITD突变阳性急性髓系白血病(FLT3-ITD(+)AML)诱导治疗的疗效及预后影响因素。 方法: 收集2013年1月至2016年12月收治的初发FLT3-ITD(+)AML患者114例,了解患者初诊时生物学特征,采用化疗方案进行诱导治疗,随访病例,并对其缓解率、预后等进行分析。 结果: 114例FLT3-ITD(+)AML患者初诊时分子学检测发现伴随预后良好基因突变52例(NPM1突变46例,RUNX1-RUNX1T1 5例,CEBPA双突变1例);其他类型FLT3-ITD(+)AML 62例。所有患者均至少完成1个疗程的诱导治疗并进行了疗效评估,1个疗程完全缓解(CR)率为50.0%(57/114),2个疗程CR率为72.5%(74/104)。52例伴随预后良好基因突变的FLT3-ITD(+)AML患者1个疗程CR率为67.3%(35/52),2个疗程CR率为83.3%(40/48);62例其他类型FLT3-ITD(+)AML患者1个疗程CR率为35.5%(22/62),2个疗程CR率为64.8%(35/54);两组CR率差异有统计学意义(P<0.05),显示FLT3-ITD伴随预后良好基因突变的AML患者治疗效果相对较好。对于其他类型FLT3-ITD(+)AML 1个疗程未缓解的患者,随后采用索拉非尼联合化疗的9例患者中6例达到CR,缓解率为66.7%;采用常规化疗方案的23例患者中7例达到CR,缓解率为30.4%,两者之间差异有统计学意义(χ(2)=4.47,P<0.05),显示索拉非尼联合化疗方案可以显著提高FLT3-ITD(+)AML不缓解患者的CR率。索拉非尼联合化疗与常规方案化疗患者总生存和无病生存比较,差异均无统计学意义(P值分别为0.641和0.517)。 结论: FLT3-ITD(+)AML患者整体预后不良,通过索拉非尼联合化疗的方案对不伴随预后良好基因突变的FLT3-ITD(+)AML进行分层治疗可以提高疗效。.
引用
- Jia JS, Zhu HH, Gong LZ, et al. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31207705. doi:10.3760/cma.j.issn.0253-2727.2019.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。